Skip to content
Clinical Trials – home

CCAB Centro Clinico Academico Braga Associacao

Research site

Portugal Lugar De Sete Fontes S Victor, 4710-243 Braga, Portugal

  • 86 trials recruiting
  • Colitis ulcerative · Multiple sclerosis · Crohn's disease
  • Adults and children

About Specializations

CCAB Centro Clinico Academico Braga Associacao in Braga, Portugal specialises in clinical trials of conditions such as Colitis ulcerative, Multiple sclerosis, Crohn's disease, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology and Immune-Mediated Skin Disease

At CCAB Centro Clinico Academico Braga Associacao, dermatology research is strongly focused on skin and connective tissue diseases and broader immune system diseases, with studies centered on conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, urticaria, and bullous pemphigoid. These trials are designed to test new treatment options, improve symptom control, and better understand how inflammatory skin disorders respond to therapy.

  • Evaluation of new therapies for moderate to severe inflammatory skin conditions
  • Research in chronic disorders such as hidradenitis suppurativa, psoriasis, and atopic dermatitis
  • Studies aiming to improve long-term disease control and patient quality of life

The site’s dermatology portfolio reflects a broad interest in immune-mediated inflammation and practical treatment advances for patients with persistent skin disease.

Gastroenterology and Inflammatory Bowel Disease

A major part of the research landscape covers digestive system diseases, especially Crohn’s disease, ulcerative colitis, and related inflammatory bowel diseases. Trials at the Braga site explore whether newer therapies can induce remission, maintain disease control, and support better outcomes in both adult and pediatric patients.

  • Clinical studies in Crohn’s disease and ulcerative colitis
  • Research on therapies for moderate to severe intestinal inflammation
  • Work aimed at improving remission rates and long-term disease management

This area also includes related digestive conditions such as erosive esophagitis and irritable bowel syndrome, showing a wide gastroenterology focus.

Neurology, Psychiatry, and Cognitive Disorders

The site has an active program in nervous system diseases and mental disorders, including multiple sclerosis, Parkinson’s disease, epilepsy, migraine, Alzheimer’s disease, dementia, schizophrenia, and obsessive-compulsive disorder. These studies are generally intended to evaluate treatment effectiveness, reduce symptoms, and support longer-term neurological and psychiatric care.

  • Trials in multiple sclerosis and other chronic neurological conditions
  • Studies in cognitive decline, dementia, and Alzheimer’s disease
  • Research on symptom control in migraine, epilepsy, and psychiatric disorders

This portfolio highlights a strong interest in both disease-modifying therapies and approaches that improve day-to-day functioning.

Oncology and Hematologic Malignancies

Cancer research at the site spans neoplasms and hemic and lymphatic diseases, with studies in breast cancer, lung cancer, prostate cancer, gastric cancer, urothelial carcinoma, head and neck cancer, lymphoma, multiple myeloma, myelofibrosis, and myeloid leukemia. The overall goal is to test innovative therapies, compare treatment strategies, and improve outcomes in difficult-to-treat cancers.

  • Studies of new cancer treatments across solid tumors and blood cancers
  • Research focused on advanced, relapsed, or metastatic disease
  • Trials evaluating better ways to extend survival and control progression

CCAB Centro Clinico Academico Braga Associacao is especially active in oncology research that seeks more effective and durable treatment responses.

Cardiovascular, Metabolic, and Kidney Disease Research

Another important theme is cardiovascular diseases together with nutritional and metabolic diseases and kidney disorders. Trials include myocardial infarction, heart failure, calcific aortic valve stenosis, hypertension, obesity, type 2 diabetes, chronic kidney disease, IgA nephropathy, and focal segmental glomerulosclerosis. These studies aim to improve disease control, slow progression, and reduce long-term complications.

  • Research on heart, vascular, metabolic, and renal conditions
  • Studies assessing treatment effectiveness and prevention of disease progression
  • Trials supporting better management of inflammation-linked cardiometabolic risk

The breadth of this area shows a strong interest in chronic diseases where early intervention can make a major difference.

Respiratory, Infectious, and Autoimmune Conditions

The site also investigates respiratory tract diseases, bacterial infections and mycoses, and virus diseases, alongside several immune system diseases. Research includes asthma, COPD, idiopathic pulmonary fibrosis, pneumonia, nontuberculous mycobacterial lung infection, and autoimmune disorders such as systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis. These trials are aimed at testing new therapies, improving safety, and helping patients with chronic inflammatory or infectious disease.

  • Studies in chronic lung disease and fibrotic respiratory conditions
  • Research on infections affecting the lungs and respiratory system
  • Trials in autoimmune diseases with systemic inflammation

This mix of respiratory, infectious, and autoimmune research reflects a broad clinical focus beyond dermatology alone.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Lugar De Sete Fontes S Victor4710-243 BragaPortugal
Recruiting now
86 trials
Conditions studied
132

More sites in BragaPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

213 clinical trials

Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Seltorexant
  • Sponsor:Janssen Cilag International

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.